AQUEOUS FORMULATION AND IN-SYRINGE AQUEOUS FORMULATION, AND ANTIBODY PROTEIN DEAGGREGATION AGENT AND ANTIBODY PROTEIN DEAGGREGATION METHOD

摘要

An aqueous formulation comprises ustekinumab, at least one selected from histidine and salts thereof, and water, whereina content of the histidine and/or the salts thereof is 50 to 90 mM in terms of histidine.